Page last updated: 2024-09-22

6-bromo-2-naphthol

Description

6-bromo-2-naphthol: RN given refers to cpd with specified bromide locant [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

6-bromo-2-naphthol : A member of the class of naphthols that is 2-naphthol carrying an additional bromo substituent at position 6. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID27144
CHEBI ID34466
SCHEMBL ID49667
MeSH IDM0106699

Synonyms (63)

Synonym
BIDD:ER0052
AC-12234
BB 0220620
bromo-6 naphtol-2 [french]
einecs 239-279-0
ai3-18464
2-naphthol, 6-bromo-
nsc 17563
2-naphthalenol, 6-bromo-
nsc17563
15231-91-1
nsc-17563
6-bromo-.beta.-naphthol
inchi=1/c10h7bro/c11-9-3-1-8-6-10(12)4-2-7(8)5-9/h1-6,12
6-bromo-2-naphthol
6-bromo-2-naphthol, 97%
B0621
HMS1651O22
6-bromonaphthalen-2-ol
AKOS000120485
6-bromo-naphthalen-2-ol
bromo-6 naphtol-2
87f10ahz3o ,
unii-87f10ahz3o
FT-0601033
AM20060520
F0701-0028
6-bromo2-hydroxynaphthalene
SCHEMBL49667
B-8922
2-hydroxy-6-bromonaphthalene
6-hydroxy-2-bromonaphthalene
2-bromo-6-hydroxynaphthalene
6-bromo-2-naphthalinol
6-bromo-beta-naphthol
CHEBI:34466
TS-00535
2-bromo-6-hydroxy-naphthalene
2-bromo-6-naphthol
6-bromo2-naphthol
6-bromo-2-napthol
6-bromo-naphthalene-2-ol
6-bromonaphth-2-ol
6-bromonapthalen-2-ol
6-bromo-2-hydroxynaphthalene
6-bromonaphthalene-2-ol
6bromo-2-naphthol
6-bromo-2-naphthalenol
6-bromo- 2hydroxynaphthalene
2-hydroxy-6-bromo-naphthalene
6-bromo-2-naphtol
W-201358
STR02406
mfcd00004081
DTXSID5074551
STL451630
CS-W001952
SY006200
(e)-hydrazinecarbohydrazonamide hydrochloride
Q27116088
EN300-17905
A851722
Z57074412

Drug Classes (2)

ClassDescription
naphtholsAny hydroxynaphthalene derivative that has a single hydroxy substituent.
organobromine compoundA compound containing at least one carbon-bromine bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (11.11)18.7374
1990's0 (0.00)18.2507
2000's2 (22.22)29.6817
2010's4 (44.44)24.3611
2020's2 (22.22)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]